Frontiers | The Role of Immunotherapy in Urothelial Cancer

The Role of Immunotherapy in Urothelial Cancer

1,848
Total downloads
6,832
Total views and downloads

Articles

SYSTEMATIC REVIEW

Accepted on 15 Jan 2025

Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis

Weiming Liang
ZHILONG HUANG
Yanping Huang
Chunyan Li
Yiwen Liang
Miaoyan Huang
Duo Zhang

doi 10.3389/fimmu.2025.1430673

ORIGINAL RESEARCH

Published on 18 Dec 2024

Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer

Chengbiao Chu
Yao Fu
Jun Yang
Xiangshan Fan
Jiong Shi

doi 10.3389/fonc.2024.1437006

327 views

CASE REPORT

Published on 11 Nov 2024

Case report: Radical robotic nephroureterectomy after chemotherapy followed by avelumab in a patient with node-positive UTUC

Hana Studentova
Vladimir Student
Daniela Kurfurstova
Andrea Kopova
Bohuslav Melichar

doi 10.3389/fonc.2024.1465213

384 views

CASE REPORT

Published on 25 Sep 2024

Case report: Toripalimab plus anlotinib in postoperative recurrent renal pelvic sarcomatoid urothelial carcinoma

Xinrong Hu
Lin Deng
Yufei Pan
Guozhen Zhang
Xiaolan Ruan
Xinlan Jiang
Hao Shen
Lei Zhao
Jun Dong

doi 10.3389/fonc.2024.1397855

811 views
1 citation

MINI REVIEW

Published on 30 Aug 2024

PD-L1 expression and correlation with outcome in muscle-invasive and metastatic urothelial carcinoma: review and critical discussion

Tämer El Saadany
Anja Lorch
Matthew I. Milowsky
Ursula Maria Vogl
Richard Cathomas

doi 10.3389/fonc.2024.1427452

610 views

ORIGINAL RESEARCH

Published on 03 Jun 2024

Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program

Se Hoon Park
Sang Joon Shin
Sun Young Rha
Seung-Hoon Beom
Ho Kyung Seo
Bhumsuk Keam
Miso Kim
Yoon-Hee Hong
Shinkyo Yoon
Jae-Lyun Lee

doi 10.3389/fonc.2024.1403120

1,268 views
1 citation

CASE REPORT

Published on 28 May 2024

Avelumab maintenance therapy for node-positive muscle invasive bladder cancer: a report of two cases

Darren M. C. Poon
Lap Yin Ho
Yiu Ming Kwong

doi 10.3389/fonc.2024.1397738

874 views

CASE REPORT

Published on 26 Mar 2024

Case report: Urachal perivascular epithelioid cell tumor

Mengru Liu
Pan Liang
Dongbo Lyu
Bingbing Zhu
Jianbo Gao

doi 10.3389/fonc.2024.1324193

566 views
1 citation

Share on

Frontiers in Oncology

Genitourinary Oncology

Impact

6,832Topic views
4,240Article views
1,848Article downloads

View impact

Submit your idea

Articles

Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis

Stromal immune cells expression of Siglec-15 is associated with lower T stage and better prognosis of urinary bladder cancer

Case report: Radical robotic nephroureterectomy after chemotherapy followed by avelumab in a patient with node-positive UTUC

Case report: Toripalimab plus anlotinib in postoperative recurrent renal pelvic sarcomatoid urothelial carcinoma

PD-L1 expression and correlation with outcome in muscle-invasive and metastatic urothelial carcinoma: review and critical discussion

Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program

Avelumab maintenance therapy for node-positive muscle invasive bladder cancer: a report of two cases

Case report: Urachal perivascular epithelioid cell tumor

Frontiers in Oncology

Impact